Approximately 9,000 CVS locations will begin selling Wegovy for $499 per month to customers who pay cash out of pocket.

CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...

Shares of CVS Health jumped after the company reported a strong first quarter and agreed to open up access to Novo Nordisk's weight-loss medication at more affordable prices. The stock was up 8.7% at ...

CVS Health ( NYSE: CVS) on Thursday announced plans to discontinue operations in the individual health insurance business, ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...